Clients

Salarius Pharmaceuticals, Inc.

Company Snapshot: Salarius Pharmaceuticals, Inc.

SLRX
Last Change Volume High Low

Company Overview

Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Client News

  1. May 18 2022 Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
  2. May 12 2022 Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
  3. May 11 2022 Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
  4. May 5 2022 Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress